D-dimer Testing Market by Products (Analyzers and Reagents & Consumables), Test Types (Clinical Laboratory Tests and Point-of-care Tests), Testing Methods (Enzyme-linked Immunosorbent Assays, Latex-enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, and Others), Applications (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, and Others), End-users (Hospitals, Academic & Research Institutes, Diagnostic Centers, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global D-dimer testing market size was valued at USD 1.19 billion in 2019 and is estimated to expand at a considerable CAGR during the forecast period, 2021-2028. The growth of market is attributed to rising demand of advanced point-of-care testing, increase incidence rate of respiratory and cardiovascular diseases, and impact of the COVID-19 pandemic outbreak.

D-dimer, also known as fibrin degradation fragment, is a protein fragment occurs in bloodstream when fibrinolysis takes place for breakdown of blood clot formed when injured.  During the process of fibrinolysis, the clumps present in blood gets broken down; after completion of degradation, number of clots is remained in blood known as D-dimers. Medical professionals used to carry out d-dimer testing by extracting blood sample by using needle to take specimens for further examination to identify existence of serious blood clot.

D-dimer test is performed when symptoms of blood clotting disorder occurred such as leg pain & swelling, shortness of breathing, nasal congestion, chest pain, and rise in heartbeat, This test is used for diagnosis of various thrombotic disorders such as deep vein thrombosis (DVT) in which clot floats in deep vein of lower legs followed by other organs of body. Pulmonary embolism (PE) is occurred due to obstruction of arteries in respiratory systems and disseminated intravascular coagulation (DIC). As a result, some severe conditions that involve the formation of blood clot to a large extent, which can cause organ failure and stroke due to the obstruction of blood flow to the central nervous system. The test utilises monoclonal antibodies of latex particles incorporated D-dimer that increases the molecular weight of the immuno complexes of the test specimen. The changes observed in turbidity of specimen are examined by photometrical analysers and turbidimetric analysers.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of pathophysiological conditions such as various cardiovascular disorders, acute pulmonary syndromes, arterial or venous thromboembolism, cardiac arrythmias, and acute pancreatitis are key driver for the rising demand for the testing.
• Rising number of geriatric populace who are exposed to severe health risks is expected to boost the market. .
• Availability of low-cost diagnosis along with highly precise results and lesser radiological interventions are key factors driving the market growth during the forecast period.
• Rising demand for advanced point-of-care testing due to lessen time of treatment and reduces time of patient stay in hospital is projected to propel the market growth in the upcoming years.
• Presence of heterophilic antibodies prevent the accurate test results of D-dimer testing in the clinical intervention of cardiovascular and pulmonary diseases. This is projected to hinder the market growth in the upcoming years.
• The development of aptamers, peptide that bind to target receptor, lessen use of antibodies in D-dimer testing. These aptamers are offering higher shelf life of monoclonal antibodies, which can offer profitable opportunities for the market growth.
• The outbreak of the COVID-19 pandemic are creating opportunities for expansion of D-dimers market due to rising demand of advance diagnostic tools and testing kits.

Scope of the Report

The report on the global D-dimer testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global D-dimer Testing Market Segment Insights

Reagents & consumables segment is expected to grow at a rapid pace

Based on products, the global D-dimer testing market is bifurcated into analyzers and reagent & consumables. The reagent & consumables segment accounted for a key share of the market in terms of revenue in 2020. Increase selling of reagents and testing kits, wide accessibility of extemporaneous reagents, and emergence of highly sophisticated robotic D-dimer assay are the key factors that expected to expand the segment during the forecast period. However, the analyzers segment is anticipated to expand at a rapid pace during the forecast period owing to reduction in laboratory time along with increasing clinical research that expected to augmentation of market growth.

Clinical laboratory tests segment is estimated to constitute a key share

On the basis of test types, the market is classified into clinical laboratory tests and point-of-care tests. The clinical laboratory tests segment held a major market share in terms of revenue in 2020 and is anticipated to constitute a dominant share of the market in the coming years. The growth of the segment is due to emergence of highly sophisticated D-dimer assays employed for the diagnosis of disseminated intravascular coagulation. Furthermore, the point-of-care tests segment are estimated to exhibit robust growth during the forecast period owing to introduction of various automated methods. The growth of the segment is attributed to excellent design, improved patient care, lesser maintenance charges, reduced risk of errors, and lesser time of diagnosis.  The constant efforts of Research & development to develop fast pace point-of-care test are estimated to boost the segment growth.

Enzyme-Linked Immunosorbent Assays segment is estimated to represent a key share

In terms of testing methods, the global D-dimer testing market is classified into enzyme-linked immunosorbent assay (ELISA), latex-enhanced immunoturbidimetric assays, fluorescence immunoassays, and others. The ELISA segment held a major market share in terms of revenue in 2020. The microplate ELISA is a reference procedure owing to its high sensitivity towards coagulation biological factors. The emerging automated ELISA assays such as VIDAS method is expected to propel the segment growth. Furthermore, the fluorescence immunoassay segment is anticipated to register a high CAGR during the forecast period due to rising demand of automated fluorescence immunoassay method for D-dimer testing. These assays provide accurate results due to its higher sensitivity and employed affordable reagents.

Deep vein thrombosis segment to represent a dominant key share

On the basis of applications, the global D-dimer testing market is divided into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others. The deep vein thrombosis segment accounted for a dominant market share and is expected to register a robust CAGR during the forecast period. The growth of market is attributed to increasing the incidence of deep vein thrombosis with risk of complications such difficulty in diagnosis and hinder movement of hospitalised patients. Patients undergone various surgeries are at higher risk of deep vein thrombosis, which simultaneously increase admittance in hospitals and drug treatment. These are the key factors that propel the segment growth in the upcoming years.

Hospital segment is expected to grow at rapid pace

Based on end-users, the market is segmented into hospitals, academic & research institutes, diagnostic centers, and others. The hospitals segment is accounted for a dominant market share and is expected to represent a major share of the market from 2021 to 2028. The growth of segment is attributed to increasing hospital admittance rate of patients along with enhancement in pulmonary embolism cases across the globe. Furthermore, the diagnostic centers segment is expected to register vigorous CAGR during the forecast period due to low-cost diagnosis and treatment provided by diagnostic centers with enhancement in the patient satisfaction.

North America is projected to account for a key share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in terms of revenue and is projected to account for a key market share in the coming years. The regional market growth is mainly due to wide clinical applications of blood clotting testing stimulated by regulatory bodies that involve in the management of coagulation testing. On the other hand, the market in Asia Pacific is expected to grow at a rapid pace during the forecast period owing to government initiative for awareness of coagulation tests. These initiatives help medical professionals, which ultimately cause increasing demand for d-dimer test in the region.

Segments

• Analyzers
• Reagents & Consumables

• Clinical Laboratory Tests
• Point-of-care Tests

• Enzyme-Linked Immunosorbent Assays
• Latex-Enhanced Immunoturbidimetric Assays
• Fluorescence Immunoassays
• Others

• Deep Vein Thrombosis
• Pulmonary Embolism
• Disseminated Intravascular Coagulation
• Others

• Hospitals
• Academic & Research Institutes
• Diagnostic Centers
• Others

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories Inc.
• Siemens Healthcare AG
• Bio-Rad Laboratories Inc
• Thermo Fisher Scientific
• Laboratory Corporation of America Holdings (LabCorp)
• Arup Laboratories
• Diazyme Laboratories Inc
• BioMerieux SA
• Sekisui Diagnostics LLC
• BioMedica Diagnostics LLC
• Becton
• Dickinson & Company
• Helena Biosciences
• Quidel Corporation

Competitive Landscape

Some of the key players competing in the market are F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Siemens Healthcare AG; Bio-Rad Laboratories Inc; Thermo Fisher Scientific; Laboratory Corporation of America Holdings (LabCorp); Arup Laboratories; Diazyme Laboratories, Inc; BioMerieux SA; Sekisui Diagnostics LLC; BioMedica Diagnostics LLC; Becton, Dickinson & Company; Helena Biosciences, and Quidel Corporation.

Many of these key players are actively investing in research & development to develop new technologies and actively engaged in various market strategies such as product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe. For instance, in 2017, Abbott Laboratories Inc., announced that it introduced alinity Ci-series. In, April 2019 Diazyme Laboratories introduced its D-dimer assay technique to expand its testing operation.